Leerink Partnrs Issues Optimistic Outlook for NAMS Earnings

Key Points

• Leerink Partners has raised its Q3 2025 earnings per share estimate for NewAmsterdam Pharma from ($0.47) to ($0.41), indicating increased optimism for the company's financial performance.
• A recent report from Citigroup and other analysts includes a "buy" rating for NewAmsterdam Pharma, with target prices ranging from $27.00 to $44.00, suggesting strong investor confidence.
• NewAmsterdam Pharma reported a quarterly loss of ($0.15) EPS, outperforming expectations significantly, and generated revenues of $19.15 million, far exceeding the consensus estimate of $1.44 million.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) - Leerink Partnrs boosted their Q3 2025 earnings per share estimates for NewAmsterdam Pharma in a report issued on Wednesday, August 6th. Leerink Partnrs analyst R. Ruiz now forecasts that the company will post earnings of ($0.41) per share for the quarter, up from their prior forecast of ($0.47). The consensus estimate for NewAmsterdam Pharma's current full-year earnings is ($1.75) per share. Leerink Partnrs also issued estimates for NewAmsterdam Pharma's Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($1.57) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($1.82) EPS and FY2028 earnings at ($0.43) EPS.

A number of other analysts also recently commented on NAMS. Citigroup assumed coverage on NewAmsterdam Pharma in a research report on Tuesday, June 17th. They set a "buy" rating and a $42.00 target price on the stock. Wall Street Zen upgraded NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research report on Saturday, July 5th. Cantor Fitzgerald assumed coverage on NewAmsterdam Pharma in a research report on Wednesday, June 4th. They set an "overweight" rating and a $42.00 target price on the stock. Stifel Nicolaus assumed coverage on NewAmsterdam Pharma in a research report on Tuesday, June 10th. They set a "buy" rating and a $44.00 target price on the stock. Finally, The Goldman Sachs Group assumed coverage on NewAmsterdam Pharma in a research report on Thursday, July 17th. They set a "neutral" rating and a $27.00 target price on the stock. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $41.20.

NewAmsterdam Pharma Stock Performance

NAMS opened at $25.31 on Monday. The business's fifty day moving average is $20.73 and its two-hundred day moving average is $19.98. The company has a market cap of $2.84 billion, a price-to-earnings ratio of -15.62 and a beta of -0.02. NewAmsterdam Pharma has a one year low of $14.06 and a one year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.52) by $0.37. The firm had revenue of $19.15 million for the quarter, compared to the consensus estimate of $1.44 million. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of institutional investors have recently made changes to their positions in NAMS. Letko Brosseau & Associates Inc. acquired a new position in NewAmsterdam Pharma in the second quarter valued at $213,000. Geode Capital Management LLC increased its stake in NewAmsterdam Pharma by 15.9% in the second quarter. Geode Capital Management LLC now owns 99,457 shares of the company's stock valued at $1,800,000 after purchasing an additional 13,629 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in NewAmsterdam Pharma in the second quarter valued at $6,392,000. Teacher Retirement System of Texas acquired a new position in NewAmsterdam Pharma in the second quarter valued at $212,000. Finally, Aberdeen Group plc increased its stake in NewAmsterdam Pharma by 95.0% in the second quarter. Aberdeen Group plc now owns 735,032 shares of the company's stock valued at $13,311,000 after purchasing an additional 358,169 shares during the last quarter. 89.89% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director James N. Topper purchased 8,584 shares of the business's stock in a transaction dated Monday, June 16th. The stock was bought at an average cost of $19.50 per share, with a total value of $167,388.00. Following the completion of the acquisition, the director directly owned 3,022,153 shares in the company, valued at $58,931,983.50. The trade was a 0.28% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Douglas F. Kling sold 100,000 shares of the business's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $19.29, for a total value of $1,929,000.00. Following the completion of the transaction, the chief operating officer directly owned 44,000 shares of the company's stock, valued at approximately $848,760. This trade represents a 69.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders bought 12,364 shares of company stock valued at $236,839 and sold 198,612 shares valued at $4,025,887. Insiders own 20.84% of the company's stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.